DB0 Stock Overview
A clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Q32 Bio Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.60 |
| 52 Week High | US$46.40 |
| 52 Week Low | US$17.20 |
| Beta | 0 |
| 11 Month Change | -41.28% |
| 3 Month Change | -26.86% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 43.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| DB0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -22.9% | -0.7% | -0.02% |
| 1Y | n/a | -17.2% | 8.2% |
Return vs Industry: Insufficient data to determine how DB0 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how DB0 performed against the German Market.
Price Volatility
| DB0 volatility | |
|---|---|
| DB0 Average Weekly Movement | 10.6% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: DB0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine DB0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 43 | Jodie Morrison | www.q32bio.com |
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata.
Q32 Bio Inc. Fundamentals Summary
| DB0 fundamental statistics | |
|---|---|
| Market cap | €287.16m |
| Earnings (TTM) | -€58.20m |
| Revenue (TTM) | n/a |
-20.4x
P/S Ratio-4.9x
P/E RatioIs DB0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DB0 income statement (TTM) | |
|---|---|
| Revenue | -US$14.66m |
| Cost of Revenue | US$45.94m |
| Gross Profit | -US$60.60m |
| Other Expenses | US$12.00k |
| Earnings | -US$60.61m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.98 |
| Gross Margin | 413.31% |
| Net Profit Margin | 413.39% |
| Debt/Equity Ratio | 83.5% |
How did DB0 perform over the long term?
See historical performance and comparison